Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice
| Autor: | Qin Feng, Shuang Li, Xin Wang, Zi-ming An, Qian Liu, Yi-Yang Hu, Lixin Zhu, Xin Xin, Bei-yu Cai |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
0301 basic medicine medicine.medical_specialty Blood lipids 030226 pharmacology & pharmacy General Biochemistry Genetics and Molecular Biology Mice 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Insulin resistance Non-alcoholic Fatty Liver Disease Internal medicine Nonalcoholic fatty liver disease Animals Hypoglycemic Agents Medicine General Pharmacology Toxicology and Pharmaceutics Triglyceride business.industry Liraglutide Fatty liver Lachnospiraceae General Medicine Lipid Metabolism medicine.disease Gastrointestinal Microbiome 030104 developmental biology Endocrinology Diabetes Mellitus Type 2 chemistry Steatosis business medicine.drug |
| Zdroj: | Life Sciences. 261:118457 |
| ISSN: | 0024-3205 |
| DOI: | 10.1016/j.lfs.2020.118457 |
| Popis: | Aims Liraglutide, a glucagon-like peptide-1(GLP-1) analog, is effective for the treatment of type II diabetes and nonalcoholic fatty liver disease (NAFLD). It was proved that gut microbiome plays a role in the development of NAFLD. This study aims to observe the therapeutic effect of liraglutide on nonalcoholic fatty liver (NAFL) in mice and effect on the gut microbial community. Main methods The db/db mice were used as the NAFL model, and lactulose was used as the positive control drug. Hepatic triglyceride, liver histopathology, and indices of glucolipid metabolism, including fasting blood glucose, fasting insulin, insulin resistance index and blood lipids were evaluated after treatment of liraglutide or lactulose for four weeks. The colonic microbiome of the mice was analyzed by 16S rRNA gene sequencing. Key findings Liraglutide significantly reduced the hepatic triglyceride (TG) content, alanine aminotransferase (ALT) activity, fasting blood glucose, insulin resistance and serum low density lipoprotein (LDL) in the db/db mice. In terms of hepatic pathologies, hepatic steatosis was significantly improved after liraglutide treating. Microbiome analysis revealed that liraglutide significantly increased the abundance of Akkermansia, Romboutsia, norank_f_Bacteroidales_S24-7_group, and decreased the abundance of Klebsiella, Anaerotruncus, Bacteroides, Lachnospiraceae_UCG-001, Lachnospiraceae_NK4A136_group, Ruminiclostridium, uncultured_f__Ruminococcaceae, and Desulfovibrio. Significance The results of the present study suggested that liraglutide had a certain therapeutic effect on fatty liver in db/db mice and had an impact on the composition of the intestinal microflora, especially some bacteria related to glucolipid metabolism and intestinal inflammation. Affecting gut microbiome might be a potential mechanism of liraglutide in treating NAFL. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect